Non-alcoholic Fatty Liver Diseases (NAFLD) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Semaglutide alters gut microbiota and improves NAFLD in db/db mice
In this study, we used a gene mutation mouse model (db/db mice) to investigate the potential liver-improving effects of semaglutide. The results showed that semaglutide improved lipid levels and glucose metabolism in db/db mice. HE staining and oil red staining showed alleviation of liver damage and reduction of hepatic lipid deposition after injection of semaglutide. In addition, semaglutide also improved the integrity of gut barrier and altered gut microbiota, especially Alloprevotella, Alistpes, Ligilactobacillus and Lactobacillus. In summary, our findings validate that semaglutide induces modifications in the compositi...
Source: Biochemical and Biophysical Research communications - April 7, 2024 Category: Biochemistry Authors: Tuohua Mao Chenxuan Zhang Shuang Yang Yingying Bi Man Li Jia Yu Source Type: research

Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
AbstractNumerous studies have compared outcomes of liver resection (LR) of patients with non-alcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) to those of patients with non-NAFLD-related HCC. However, results have been inconsistent. We aim to clarify this issue. We enrolled 801 patients with hepatitis B virus (HBV)-related HCC, 433 patients with hepatitis C virus (HCV)-related HCC, and 128 patients with NAFLD-related HCC undergoing LR. Overall survival (OS) and disease-free survival (DFS) of patients with different etiologies of chronic liver disease was compared using the Kaplan –Meier estimat...
Source: Updates in Surgery - April 7, 2024 Category: Surgery Source Type: research

TET3 boosts hepatocyte autophagy and impairs non-alcoholic fatty liver disease by increasing ENPP1 promoter hypomethylation
CONCLUSIONS: We describe a novel epigenetic mechanism wherein TET3 promoted ENPP1 expression through promoter hypomethylation is a critical mediator of NAFLD. Our findings provide new insight into the development of preventative measures for NAFLD.PMID:38582229 | DOI:10.1016/j.freeradbiomed.2024.04.207 (Source: Free Radical Biology and Medicine)
Source: Free Radical Biology and Medicine - April 6, 2024 Category: Biology Authors: Feng Sun Yang Yang Lin Jia Qi-Qi Dong Wei Hu Hui Tao Chao Lu Jing-Jing Yang Source Type: research

Radiomics-based prediction of nonalcoholic fatty liver disease following pancreatoduodenectomy
ConclusionsPreoperative CT-derived radiomic features from the pancreatic and liver regions are promising for the prediction of NAFLD post-PD. Using these features enhances the predictive model, enabling earlier intervention for high-risk patients. (Source: Surgery Today)
Source: Surgery Today - April 6, 2024 Category: Surgery Source Type: research

The interplay between diabetes and non-alcoholic fatty liver disease: a cross-sectional study from Pakistan
CONCLUSION: There is a positive association between elevated HbA1c and ALT levels in T2DM patients with NAFLD.PMID:38576946 | PMC:PMC10990318 | DOI:10.1097/MS9.0000000000001875 (Source: Annals of Medicine)
Source: Annals of Medicine - April 5, 2024 Category: Internal Medicine Authors: Ayesha Akhtar Huda Ijaz Maria Waseem Muhammad Ijaz Khan Yasir Saif Haris Iqbal Syeda Aasia Batool Usha Kumari Salim Surani Aarash Khan Source Type: research

Sex and racial disparities in non-alcoholic fatty liver disease-related cardiovascular events: National inpatient sample analysis (2019)
CONCLUSION: Increasing age and male sex link NAFLD with adverse MACCE outcomes; Native Americans and Asian Pacific Islanders face higher mortality, highlighting a need for tailored interventions and care.PMID:38576521 | PMC:PMC10989223 | DOI:10.4330/wjc.v16.i3.137 (Source: World Journal of Cardiology)
Source: World Journal of Cardiology - April 5, 2024 Category: Cardiology Authors: Rupak Desai Ali Tariq Alvi Advait Vasavada Yashwitha Sai Pulakurthi Bhavin Patel Adil Sarvar Mohammed Shreyans Doshi Ikechukwu Ogbu Source Type: research

Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis
CONCLUSION: Hepatic steatosis lowers the biochemical response to antiviral treatment in patients with CHB.PMID:38577526 | PMC:PMC10989305 | DOI:10.4254/wjh.v16.i3.465 (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - April 5, 2024 Category: Gastroenterology Authors: Shi-Yi Liu Dian Wang Jing Liu Lu-Ping Yang Gong-Ying Chen Source Type: research

Non-alcoholic fatty liver disease and sleep disorders
World J Hepatol. 2024 Mar 27;16(3):304-315. doi: 10.4254/wjh.v16.i3.304.ABSTRACTStudies have shown that non-alcoholic fatty liver disease (NAFLD) may be associated with sleep disorders. In order to explore the explicit relationship between the two, we systematically reviewed the effects of sleep disorders, especially obstructive sleep apnea (OSA), on the incidence of NAFLD, and analyzed the possible mechanisms after adjusting for confounding factors. NAFLD is independently associated with sleep disorders. Different sleep disorders may be the cause of the onset and aggravation of NAFLD. An excessive or insufficient sleep du...
Source: World Journal of Hepatology - April 5, 2024 Category: Gastroenterology Authors: Lu-Fang Bu Chong-Yu Xiong Jie-Yi Zhong Yan Xiong Dong-Ming Li Fen-Fang Hong Shu-Long Yang Source Type: research

Update in lean metabolic dysfunction-associated steatotic liver disease
CONCLUSION: MASLD is a complex disease comprising epigenetic, genetic, and metabolic factors in its pathogenesis. Results vary across populations, gender, and age. Limited data exists on clinical practice guidelines for lean patients. Future studies employing this new nomenclature can contribute to standardizing and generalizing results among lean patients with steatotic liver disease.PMID:38577539 | PMC:PMC10989317 | DOI:10.4254/wjh.v16.i3.452 (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - April 5, 2024 Category: Gastroenterology Authors: Karina Sato-Espinoza Perapa Chotiprasidhi Mariella R Huaman Javier D íaz-Ferrer Source Type: research

Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis
CONCLUSIONS: Silymarin can regulate energy metabolism, attenuate liver damage, and improve liver histology in NAFLD patients. However, the effects of silymarin will need to be confirmed by further research.PMID:38579127 | DOI:10.1016/j.aohep.2023.101174 (Source: Annals of Hepatology)
Source: Annals of Hepatology - April 5, 2024 Category: Gastroenterology Authors: Shudi Li Fei Duan Suling Li Baoping Lu Source Type: research

RNA expression changes driven by altered epigenetics status related to NASH etiology
In conclusion, the chromatin landscape is altered in NASH patients compared to patients without this liver condition. This alteration might cause mRNA changes explaining, at least partially, the etiology and pathophysiology of the disease.PMID:38579398 | DOI:10.1016/j.biopha.2024.116508 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 5, 2024 Category: Drugs & Pharmacology Authors: Daniel Castellano-Castillo Bruno Ramos-Molina Mar ía Dolores Frutos Isabel Arranz-Salas Armando Reyes-Engel Mar ía Isabel Queipo-Ortuño Fernando Cardona Source Type: research